Trump’s “Super Intelligence” push and RFK Jr.’s biotech optimism spark a new AI–gene-editing power race—what’s next?

On September 30, 2026, the BBC reported takeaways from President Trump’s “Super Intelligence” summit, highlighting that he also signed an executive order requiring the U.S. government to refer to AI as “Super Intelligence.” The same day, RFK Jr. framed AI in a deliberately optimistic, anti-establishment tone, describing it as a “cure for medical tyranny,” signaling an effort to shift public and political narratives around AI-enabled healthcare. Separately, on September 29, 2026, Origin Genomics said it aims to demonstrate that the potential benefits of its technology for editing disease-causing genes in human embryos outweigh the risks. Taken together, the cluster points to a coordinated push to accelerate both AI governance and high-stakes human embryo gene-editing, with political messaging and regulatory posture moving in tandem. Strategically, this matters because it links state-level AI branding and policy direction with a broader permissive stance toward transformative biomedical technologies. The “Super Intelligence” framing can function as a political umbrella that legitimizes faster deployment, while RFK Jr.’s rhetoric suggests coalition-building with voices skeptical of conventional medical and regulatory authority. Origin Genomics’ effort to justify embryo editing benefits underscores how the U.S. biotech ecosystem is seeking to expand the permissible frontier of genetic intervention, potentially reshaping global norms and competitive dynamics. In this power contest, the likely beneficiaries are AI and biotech developers able to navigate or influence regulatory interpretation, while the main losers are institutions that rely on slower, more precautionary governance models. Market implications could be material even if the articles do not name specific tickers. AI reclassification into “Super Intelligence” may accelerate demand for compute, data infrastructure, and AI safety tooling, supporting sectors tied to cloud capacity, semiconductors, and enterprise AI services. The embryo gene-editing angle, meanwhile, raises the probability of renewed capital flows into gene-editing platforms, preclinical-to-clinical translation services, and specialized compliance and biosecurity vendors, because investors typically price regulatory clarity and trial feasibility. Currency and rates are not directly mentioned, but the direction of risk is clear: higher regulatory momentum tends to lift growth expectations for frontier-tech equities while increasing volatility around bioethics, liability, and potential future restrictions. Overall, the cluster suggests a near-term sentiment tailwind for AI and biotech, with a parallel rise in headline-driven risk premia. What to watch next is whether the executive order’s implementation details translate into concrete procurement, research funding, and interagency guidance, and whether “Super Intelligence” becomes embedded in federal standards or procurement language. For RFK Jr.’s influence, the key trigger is whether his messaging translates into legislative proposals, oversight changes, or public-private partnerships that affect AI-in-healthcare deployment. For Origin Genomics, the next critical indicators are the evidence package used to argue risk-benefit superiority, any regulatory feedback on embryo editing, and whether the company advances toward trials or faces procedural delays. Escalation risk would rise if public controversy or international scrutiny intensifies around embryo editing and AI governance; de-escalation would be signaled by transparent safety frameworks, independent review commitments, and clearer regulatory timelines.

Geopolitical Implications

• 01

  AI branding at the state level can become a de facto norm-setting lever with global competitive effects.

• 02

  A permissive stance on embryo editing may widen regulatory divergence and intensify cross-border compliance pressure.

• 03

  Narrative politics around AI and medicine can reshape oversight intensity and the speed of deployment.

• 04

  If safety frameworks remain vague, reputational and compliance risks could spill into global biotech financing.

Key Signals

• —Implementation details of the “Super Intelligence” executive order (procurement, funding, interagency guidance).
• —Any legislative or oversight moves tied to RFK Jr.’s AI-in-healthcare messaging.
• —Origin Genomics’ regulatory submissions and independent review requirements for embryo editing.
• —Public and international reaction to embryo gene-editing claims and AI governance framing.